Gloucester Pharmaceuticals Articles
BIO Investor Forum: reinventing the biotech business model
15 October 2010
Showing 1-1 of 1 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
